The biosimilar will be available in both subcutaneous and intravenous formulations and has nearly all the same indications as ...

February 2 is observed as Rheumatoid Arthritis Awareness Day to raise awareness about the condition, its causes, symptoms, treatment options, and more ...

Medically reviewed by Stella Bard, MD Osteoarthritis (OA) and rheumatoid arthritis (RA) are two of the most common types of ...

Rheumatoid Arthritis Awareness Day 2025 is observed on February 2. Created in 2013 by the Rheumatoid Patient Foundation, it is to raise awareness around the chronic autoimmune disease. Rheumatoid ...

The FDA approved Avtozma, a tocilizumab biosimilar developed by Celltrion, for the treatment of several rheumatic conditions.

JERSEY CITY, NJ, USA I January 30, 2025 I Celltrion today announced that the U.S. Food and Drug Administration (FDA) has approved AVTOZMA® (CT-P47, ...

Swiss pharma giant Roche Holding AG RHHBY posted better-than-expected 2024 results and provided an encouraging outlook for ...

The FDA accepted applications for a golimumab biosimilar, while Samsung Biologics reported record sales, and a Japanese ...

Indian biopharma company Biocon reported third-quarter revenue on Thursday that fell about 3% when compared with the year-earlier period, which included revenue from its domestic branded formulation ...

The difference between rheumatoid arthritis and osteoarthritis must be understood so that it is diagnosed on time and ...

Alvotech and Teva announced FDA acceptance of the Biologics License Application (BLA) for AVT05, a proposed biosimilar ...

The "Biologics - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.The global ...